Sorrento Therapeutics (SRNE) Starts Presentation at LD Micro Main Event
Sorrento Therapeutics (NASDAQ: SRNE) is an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors. For more information, visit the company's website atwww.sorrentotherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide…







